Zacks Research Has Bullish Estimate for PBH FY2025 Earnings

Prestige Consumer Healthcare Inc. (NYSE:PBH) – Zacks Research increased their FY2025 earnings estimates for shares of Prestige Consumer Healthcare in a research report issued on Tuesday, January 14th. Zacks Research analyst R. Department now expects that the company will earn $4.51 per share for the year, up from their prior forecast of $4.43. The consensus estimate for Prestige Consumer Healthcare’s current full-year earnings is $4.44 per share. Zacks Research also issued estimates for Prestige Consumer Healthcare’s Q1 2026 earnings at $1.02 EPS, Q4 2026 earnings at $1.30 EPS, Q1 2027 earnings at $1.12 EPS, Q2 2027 earnings at $1.24 EPS and FY2027 earnings at $4.98 EPS.

PBH has been the topic of several other reports. DA Davidson restated a “buy” rating and set a $95.00 price target on shares of Prestige Consumer Healthcare in a report on Monday, November 11th. Jefferies Financial Group reiterated a “hold” rating and set a $76.00 target price (up from $70.00) on shares of Prestige Consumer Healthcare in a research report on Tuesday, September 24th. StockNews.com cut shares of Prestige Consumer Healthcare from a “buy” rating to a “hold” rating in a research report on Thursday. Raymond James upgraded shares of Prestige Consumer Healthcare to a “moderate buy” rating in a report on Thursday, December 19th. Finally, Sidoti downgraded Prestige Consumer Healthcare from a “buy” rating to a “neutral” rating and set a $90.00 price objective for the company. in a report on Monday, December 9th. Three research analysts have rated the stock with a hold rating and two have issued a buy rating to the company. According to MarketBeat.com, Prestige Consumer Healthcare presently has an average rating of “Hold” and a consensus target price of $85.25.

Prestige Consumer Healthcare Price Performance

Shares of PBH opened at $78.31 on Thursday. The company has a quick ratio of 2.10, a current ratio of 3.56 and a debt-to-equity ratio of 0.61. The stock has a market cap of $3.87 billion, a PE ratio of 19.05, a PEG ratio of 2.08 and a beta of 0.51. Prestige Consumer Healthcare has a 12-month low of $58.22 and a 12-month high of $86.36. The business has a 50-day simple moving average of $80.56 and a two-hundred day simple moving average of $74.41.

Prestige Consumer Healthcare (NYSE:PBH) last posted its earnings results on Thursday, November 7th. The company reported $1.09 earnings per share for the quarter, hitting analysts’ consensus estimates of $1.09. Prestige Consumer Healthcare had a net margin of 18.54% and a return on equity of 12.23%. The firm had revenue of $283.79 million for the quarter, compared to analysts’ expectations of $282.09 million. During the same quarter in the previous year, the firm posted $1.07 earnings per share. The company’s revenue was down .9% on a year-over-year basis.

Institutional Trading of Prestige Consumer Healthcare

Several large investors have recently modified their holdings of PBH. Quest Partners LLC lifted its position in shares of Prestige Consumer Healthcare by 2,826.7% during the 2nd quarter. Quest Partners LLC now owns 439 shares of the company’s stock valued at $30,000 after acquiring an additional 424 shares during the period. Northwestern Mutual Wealth Management Co. raised its holdings in shares of Prestige Consumer Healthcare by 562.3% during the second quarter. Northwestern Mutual Wealth Management Co. now owns 510 shares of the company’s stock valued at $35,000 after purchasing an additional 433 shares during the period. nVerses Capital LLC boosted its position in shares of Prestige Consumer Healthcare by 200.0% during the 3rd quarter. nVerses Capital LLC now owns 600 shares of the company’s stock worth $43,000 after purchasing an additional 400 shares in the last quarter. Huntington National Bank grew its stake in shares of Prestige Consumer Healthcare by 39.9% in the 3rd quarter. Huntington National Bank now owns 635 shares of the company’s stock valued at $46,000 after buying an additional 181 shares during the period. Finally, International Assets Investment Management LLC grew its stake in shares of Prestige Consumer Healthcare by 7,112.5% in the 3rd quarter. International Assets Investment Management LLC now owns 1,154 shares of the company’s stock valued at $83,000 after buying an additional 1,138 shares during the period. Institutional investors and hedge funds own 99.95% of the company’s stock.

Insider Transactions at Prestige Consumer Healthcare

In other news, insider William P’pool sold 8,987 shares of Prestige Consumer Healthcare stock in a transaction dated Tuesday, November 12th. The stock was sold at an average price of $81.85, for a total value of $735,585.95. Following the completion of the transaction, the insider now directly owns 20,058 shares of the company’s stock, valued at approximately $1,641,747.30. This trade represents a 30.94 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is accessible through this link. Also, CEO Ronald M. Lombardi sold 10,875 shares of the business’s stock in a transaction dated Tuesday, November 19th. The shares were sold at an average price of $82.60, for a total value of $898,275.00. Following the completion of the transaction, the chief executive officer now directly owns 320,952 shares in the company, valued at $26,510,635.20. This represents a 3.28 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 38,810 shares of company stock worth $3,187,300. Company insiders own 1.60% of the company’s stock.

About Prestige Consumer Healthcare

Prestige Consumer Healthcare Inc, together with its subsidiaries, develops, manufactures, markets, distributes, and sells over-the-counter (OTC) health and personal care products in the United States and internationally. The company operates in two segments, North American OTC Healthcare and International OTC Healthcare.